Risk of malformations and other outcomes in children exposed to fluconazole in utero

Citation
Ht. Sorensen et al., Risk of malformations and other outcomes in children exposed to fluconazole in utero, BR J CL PH, 48(2), 1999, pp. 234-238
Citations number
15
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
ISSN journal
03065251 → ACNP
Volume
48
Issue
2
Year of publication
1999
Pages
234 - 238
Database
ISI
SICI code
0306-5251(199908)48:2<234:ROMAOO>2.0.ZU;2-3
Abstract
Aim Fluconazole is an active drug systematically used in the oral treatment of vaginal candidiasis and other fungal diseases. We examined the risk of malformations and other birth outcomes following pregnancy related exposure s. Method From 1 January 1991 to 31 December 1996 we identified 165 women who had taken fluconazole just before or during pregnancy in the Pregnancy Outc ome Section of the North Jutland Pharmacoepidemiological Prescription Datab ase, Denmark, which is linked to the Danish Medical Birth Registry. We comp ared their birth outcomes (malformation, low birth weight and preterm deliv ery) with the outcomes among 13 327 women who did not receive any prescript ions during their pregnancies. Results The prevalence of malformation was 3.3% (four cases) among the 121 women, who had used fluconazole in the first trimester, and 5.2% (697 cases ) in offspring to controls (odds ratio: 0.65, 95% confidence limits: 0.24-1 .77). Furthermore, we did not find any significantly elevated risk of prete rm delivery (odds ratio: 1.17, 95% confidence Limits: 0.63-2.17) and low bi rth weight (odds ratio. 1.19, 95% confidence limits: 0.37-3.79). Conclusion The study showed no increased risk of congenital malformations, low birth weight or preterm birth in offspring to women who had used single dose fluconazole before conception or during pregnancy.